Introduction
There is growing awareness and interest in the biological importance of (n-3) fatty acids, particularly as they relate to brain development, vision, aging, and neurodegenerative diseases. The (n-3) fatty acid, docosahexaenoic acid (DHA), 4 has its highest concentrations in the human body as an acyl group of phospholipids in the central nervous system, especially in photoreceptor discs and in synaptic membranes. DHA is necessary for retina and brain development (1, 2) , memory formation, synaptic function, and neuroprotection. This fatty acid has been implicated in several functions, such as those in photoreceptor biogenesis and function (3) (4) (5) , memory (6), excitable membranes functions (7) , and neuroprotection (8) . One property that the brain and retina share, with respect to (n-3) fatty acids, is their ability to retain DHA, even during extended dietary deprivation of (n-3) essential fatty acids. To efficiently reduce DHA content in brains and retinas of rodents and nonhuman primates, dietary deprivation for over 1 generation has been required, and the result was impaired retinal and brain function (9, 10) .
Epidemiological studies support the theory that (n-3) fatty acids slow down cognitive decline in the elderly (11) . On the other hand, at least 11 observational studies and 4 clinical trials did not conclusively demonstrate that DHA plays a favorable role in the prevention or treatment of dementia, including Alzheimer's disease (AD) (11) . In AD transgenic mice, dietary DHA supplementation restored cerebral blood volume, reduced (Abeta peptide) Ab deposition, ameliorated Ab pathology (12) (13) (14) , and downregulated Ab release from aged human neural cells (15) . DHA also exerts antiinflammatory and antiapoptotic actions (8, 16, 17) .
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* To whom correspondence should be addressed. E-mail: nbazan@lsuhsc.edu. 4 Abbreviations used: 15-LOX, 15-lipoxygenase; Ab, Abeta peptide; AD, Alzheimer's disease; bAPP, beta-amyloid precursor protein; cPLA(2), cytosolic phospholipase A(2); DHA, docosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; HN, human neuronal; IL-1b, interleukin-1beta; NPD1, neuroprotectin D1; PEDF, pigment epithelium-derived factor; RPE, retinal pigment epithelial; sAPPa, soluble amyloid precursor protein alpha; TNF, tumor necrosis factor. and in neurodegeneration; these products in turn form protein adducts and other cytotoxic molecules that participate in free radical-mediated injury in AD (18, 19) . The identification of the DHA-derived docosanoid neuroprotectin D1 (NPD1:10R,17S-dihydroxy-docosa-4Z,7Z,11E,15E,19Z hexaenoic acid) provides new insight into the protective bioactivity of DHA (20) (21) (22) . NPD1 elicits neuroprotective activity in brain ischemia-reperfusion ( Fig. 1) in oxidative-stressed retinal pigment epithelial (RPE) cells, and it promotes neuronal and glial cell survival (21, 22) . DNA microarray profiling suggests a downregulation of proinflammatory genes as well as of some proapoptotic genes of the Bcl-2 family in cellular AD models (15) . NPD1 further influences beta-amyloid precursor protein (bAPP) processing and the release of Ab peptides, and its precursor DHA elicits an Ablowering effect both in vitro and in vivo (23) (24) (25) .
NPD1 is reduced in the AD cornu ammonis 1 hippocampal region and the neocortex, but not in other unaffected areas of the brain. The expression of key enzymes for NPD1 biosynthesis, cytosolic phospholipase A(2) [cPLA (2)], and 15-lipoxygenase (15-LOX) are altered in the AD hippocampal cornu ammonis 1 region (15).
Neuroprotectin D1 inhibits ischemia-reperfusionmediated leukocyte infiltration and stroke size Complexing DHA to human albumin after middle cerebral artery occlusion results in high-grade neurobehavioral and histological neuroprotection using a low albumin dose (0.63 g/ kg), which in the absence of DHA is not robustly neuroprotective. The DHA-albumin complex also increases the production of NPD1 in the ipsilateral brain tissue (26, 27) .
NPD1 downregulates interleukin-1b-activated amyloid b peptide secretion during in vitro aging of neural progenitor cells Human neuronal (HN) cells, a primary coculture of human neurons and glia, are a useful in vitro test system to explore stress signaling in the human brain, aging, and AD (28) ( Fig.  2A) . As indicated by bIII tubulin and glial fibrillary acidic protein immunostaining, these cultures are mixtures of equal proportions of neurons and glia under defined growth conditions at 4 wk of development (Fig. 2B, C) . Interestingly, amyloidogenic Ab peptides were progressively secreted from HN cells throughout 8 wk of culture ( Fig. 2D, E) . The ratio of Ab40, a resident peptide of AD blood vessels, to Ab42, which aggregates at lower concentrations than Ab40 and is enriched within the amyloid plaque of AD (29), was~10:1 throughout this 8-wk period. To determine the effect of cytokine-mediated stress on aging HN cells, Ab40 and Ab42 peptide release was assayed in the incubation medium after addition of interleukin (IL)-1b, an inducer of reactive oxygen species and of oxidative stress (28, 30) . A time-dependent release of both Ab40 and Ab42 peptides as a function of the number of weeks in culture was observed. Whereas soluble Ab peptide secretion from HN cells was enhanced in the presence of interleukin-1beta (IL-1b), parallel experiments with DHA in the culture medium resulted in attenuation of Ab peptide release (Fig. 2D, E) .
Thus, HN cells use DHA as a precursor for NPD1 biosynthesis (Fig. 2F) , yielding a 5-fold increase in NPD1 pool size at 4 wk of culture; at 8 wk, the concentration of this lipid mediator was about half that observed at 4 wk (Fig. 2F ). These observations suggest that in aging HN cells, attenuation of the neurotoxic Ab peptide release by DHA could be mediated, at least in part, by NPD1.
sAPPa is an agonist for NPD1 synthesis Because DHA mediates the downregulation of Ab40 and Ab42 release and stimulates NPD1 production in HN cells, the possibility that NPD1 biosynthesis might be affected by the Neuroprotection and neural plasticity 859 neurotrophic peptide soluble amyloid precursor protein alpha (sAPPa), a 612-amino acid fragment derived from a-secretasemediated cleavage of bAPP, which appears to be neurotrophic (29) , was investigated. sAPPa induces neuritogenesis and longterm survival of hippocampal and cortical neurons in culture and protects brain cells against the toxicity of Ab40 and Ab42 peptides and excitotoxic and ischemic injury, both in cell cultures and in vivo (31) . It is important to note that the sAPPa generated via the a-secretase pathway does not give rise to the shorter amyloidogenic Ab peptides; hence, the shunting of bAPP into the a-secretase pathway may have a beneficial action as a result of the relative lowering of Ab peptide levels (29, (31) (32) (33) . A dose-dependent NPD1 induction by sAPPa (Fig. 2G) takes place under these conditions. For the additivity experiments with DHA and sAPPa, concentrations of sAPPa that elicited a small (20 mg/L) and a larger (100 mg/L) NPD1 induction were explored. sAPPa at 20 and 100 mg/L, in the presence of 50 nmol/ L of added DHA, induced NPD1 abundance 2.3-and 5-fold, respectively, over that of controls treated with DHA alone. sAPPa at 20 mg/L in the absence of added DHA elicited negligible NPD1 synthesis; however, at 100 mg/L, sAPPa stimulation strongly triggered NPD1 synthesis in the absence of added DHA. These results indicate that some of the neurotrophic activity of sAPPa may be elicited, at least in part, by an upregulation in the biosynthesis of DHA-derived NPD1. This may be a complementary cell survival mechanism activated early in AD pathogenesis. sAPPa may activate the NPD1 biosynthetic enzymes cPLA(2) and/or a 15-LOX-like enzyme integral to NPD1 biosynthesis from DHA (13) . Muscarine, a positive regulator of cPLA (2), is also a potent inducer of sAPPa in human neuroblastoma SH-SY5Y cells (34) ; therefore, the enzymatic pathways involving PLA(2)-mediated DHA and NPD1 biosynthesis may exhibit positive feedback regulation through sAPPa. sAPPa also appears to protect neural cells against the proapoptotic action of thapsigargin, an inhibitor of the endoplasmic reticulum Ca 2+ -ATPase, and the adverse effect of thapsigargin can be abolished in cells overexpressing antiapoptotic Bcl-2. This implies premitochondrial signaling for pro-and antiapoptotic Bcl-2 protein expression.
NPD1 counteracts Ab peptide-induced apoptosis in neurons and glia
Because Ab42 peptides induce apoptosis and cell death in both neurons and glia (35) , the ability of NPD1 to protect HN cells against Ab42-induced cytotoxicity was explored. For this purpose, 3-wk-old HN cells were incubated for an additional 3.5 d in serum-free HN cell maintenance medium containing 8 mmol/L in Ab42 peptide. Except for the experiments depicted in Figure 2D -F, HN cells used in these studies were used at a developmental stage of 3-4 wk in culture, at which time there were approximately equal populations of neuronal and glial HN cells ( Fig. 2A-C) . Because selective cell loss may take place in older HN cell cultures (when neuronal cells drop out), the use of HN cells at a fixed age (and 50:50 neuronal/glial populations) was selected to minimize this possibility. Apoptosis occured in both neurons and glia. When NPD1 (50 nmol/L) was added to this test system, NPD1 protected both neurons and glia from Ab42-directed apoptosis, as evidenced by quantification of Hoechst 33258 staining of compacted nuclei in control, Ab42-treated, and Ab42 +NPD1-treated cell fields. Unlike control HN cells, Ab42-treated HN cells also exhibited retracted neurites; however, when treated with NPD1, cells assumed extended neurites and an overall morphology resembling that of control cells.
15-LOX-1-catalyzed NPD1 synthesis mediates rescue from oxidative stress During ischemia-reperfusion, aspirin enhances formation in the brain of 17R-resolvins, which are counterregulators of inflammation outside the brain. It could be argued that these DHA mediators enhance NPD1 bioactivity, decrease polymorphonuclear cell recruitment to the brain, and limit brain damage. Given the wide use of aspirin, the implied switch from endogenous to aspirin-triggered NPD1, which modulates homeostasis, is of great interest to neuraceuticals and dietary studies (21) .
15-LOX-1-deficient RPE cells are more susceptible to perturbations that lead to apoptosis. The level of cell death is magnified in 15-LOX-1 deficient cells, as the concentration of oxidative stress mediators is increased. The magnitude of the response in the 15-LOX-1-deficient cells, in which the formation of NPD1 remained at low levels, was higher at 400, 600, and 800 mmol/L H 2 O 2 [plus tumor necrosis factor (TNF)-a]. These observations, along with the unchanged content of 15-LOX-1, suggest that the diminished 15-LOX-1 activity, which forms lesser amounts of NPD1, contributes to increased apoptosis in knockdown cells. The increased sensitivity of RPE cells to oxidative stress-induced apoptosis may be due to a decreased availability either of NPD1 or of other 15-LOX-1 products. DHA and pigment epitheliumderived factor (PEDF) protect RPE cells synergistically from oxidative stress-induced apoptosis. NPD1 synthesis is enhanced under these conditions (22, 36) . To corroborate that NPD1 was in fact the 15-LOX-1 product responsible for protecting RPE knockdown cells, apoptosis induced in silenced cells using 600 mmol/L H 2 O 2 and 10 mg/L TNFa was used to test protective bioactivity of PEDF and DHA, 15(S)-hydroxyeicosatetraenoic acid (HETE), 12(S)-HETE, lipoxinA4, or NPD1. Only NPD1 rescued 15-LOX-1-deficient cells from oxidative stress-induced apoptosis (Fig. 3) . PEDF and DHA treatment was protective in nonsilenced cells but did not prevent apoptosis in the knockdown cells. Added DHA conversion to NPD1 is stimulated by PEDF; however, this conversion cannot take place in silenced cells. None of the arachidonic acid oxygenation products prevented cell death induced by oxidative stress (37) .
Concluding remarks
The interplay of DHA-derived neuroprotective signaling aims to counteract proinflammatory, cell-damaging events triggered by 
FIGURE 4
Biosynthesis of NPD1. A membrane phospholipid containing a docosahexaenoyl chain in sn-2 is hydrolyzed by phospholipase A2, generating free (unesterified) DHA. The carbons of DHA are numbered and the (n-3) fatty acid tail is highlighted. Lipoxygenation is then followed by epoxidation and hydrolysis, to generate NPD1. Bioactivity is depicted with arrows (activation) and bars (inhibition). Induction of nerve regeneration refers to cornea nerve regeneration (42) (43) (44) . Adapted with permission from (44) .
Neuroprotection and neural plasticity 861 multiple, converging cytokine and amyloid peptide factors in AD. Amyloid peptide-mediated oxidative stress, the activation of microglia associated with Ab peptide deposition, and excessive production of microglial-derived cytokines, such as IL1b and TNFa, support progressive inflammatory episodes in AD (35, (38) (39) (40) . These noxious stimuli further orchestrate pathogenic gene-expression programs in stressed brain cells, thereby linking a cascade of caspase-mediated cell death pathways with apoptosis and neuronal demise (28, 41) . Neural mechanisms leading toward NPD1 generation from DHA thereby appear to redirect cellular fate toward successful brain cell aging (Fig. 4) . The Bcl-2 pro-and antiapoptotic gene families, sAPPa, and NPD1 lie along a cell fate-regulatory pathway whose component members are highly interactive and have potential to function cooperatively in brain cell survival during aging and during the onset of neurodegeneration. Overall, they operate in large part through modulation of Ab42-directed pathogenic events. Taken together, these data suggest that NPD1 induces an antiapoptotic, neuroprotective gene-expression program that regulates the secretion of Ab peptides, resulting in the modulation of inflammatory signaling, neuronal survival, and the preservation of brain cell function. Agonists of NPD1 biosynthesis or NPD1 analogs may be useful for exploring therapeutic strategies for AD and related neurodegenerative disease.
